CD
ALNY icon

Chapin Davis’s Alnylam Pharmaceuticals ALNY Stock Holding History

Chapin Davis’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$256K Buy
850
+6
+0.7% +$1.81K 0.05% 211
2026
Q1 		$279K Buy
844
+19
+2% +$6.47K 0.06% 210
2025
Q4 		$328K Hold
825
– – 0.08% 180
2025
Q3 		$376K Hold
825
– – 0.09% 169
2025
Q2 		$269K Hold
825
– – 0.07% 187
2025
Q1 		$223K Hold
825
– – 0.08% 191
2024
Q4 		$227K Hold
825
– – 0.07% 199
2024
Q3 		$227K Hold
825
– – 0.07% 200
2024
Q2 		$200K Buy
+825
New +$130K 0.07% 211

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Chapin Davis's ALNY Position: Q2 2026 in Review

Chapin Davis increased its Alnylam Pharmaceuticals (ALNY) stake by 0.71% in Q2 2026, buying an estimated $1.81K and bringing the position to 850 shares worth $256K. The position accounts for 0.05% of the portfolio, ranked #211.

Chapin Davis first reported a position in ALNY in Q2 2024 and has held it in 9 quarters since. The position peaked at $376K in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Chapin Davis held 850 shares of Alnylam Pharmaceuticals worth $256K as of Q2 2026.
  • Chapin Davis bought 6 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.81K.
  • Alnylam Pharmaceuticals made up 0.05% of Chapin Davis's portfolio in Q2 2026, its #211 holding.
  • Chapin Davis first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Chapin Davis's Alnylam Pharmaceuticals position peaked at $376K in Q3 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Chapin Davis's 13F filing for Q2 2026, filed 7 Jul 2026.